Core Viewpoint - Shenzhen Maikedian Biomedical Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International as joint sponsors. The company reported a loss of approximately RMB 40.968 million in the first half of this year [1]. Group 1: Company Overview - Maikedian is a global provider of medical solutions, offering a comprehensive product portfolio that meets clinical needs across various healthcare settings, including hospitals, community health centers, and home care [3]. - The company has commercialized over 50 life support products, 80 minimally invasive intervention products, and 210 in vitro diagnostic products, with its products available in over 140 countries and regions [3][4]. Group 2: Product Categories - In life support, Maikedian has developed innovative products, including the world's first remote infusion control system and China's first independently developed multi-channel infusion workstation. The company ranks first in the infusion workstation market in China by sales from 2018 to 2024 [3]. - In minimally invasive intervention, Maikedian is one of the few domestic brands in China with a full range of endoscopic proprietary products, ranking second in the digestive system minimally invasive intervention consumables market from 2022 to 2024 [4]. - In vitro diagnostics, Maikedian launched the world's first fully automated thromboelastography analyzer in 2021 and ranks first in the market for this product in China from 2021 to 2024 [4]. Group 3: Financial Performance - The company's revenue for the fiscal years 2022, 2023, and 2024, as well as for the six months ending June 30, 2025, were approximately RMB 917 million, RMB 1.313 billion, RMB 1.399 billion, and RMB 787 million, respectively. The losses for the same periods were approximately RMB 226.161 million, RMB 64.508 million, RMB 96.617 million, and RMB 40.968 million [5][6].